Southeast Asia's Prefilled Syringes Market Expected to Grow 8.77% to Reach USD Million by 2033, According to UnivDatos.

Key Highlights of the Report:

• Southeast Asia Prefilled Syringes market is experiencing a high growth rate due to the increasing rate of biologics and vaccine acceptance, and the larger self-injection motions in therapeutic fields such as diabetes and autoimmune diseases.

• Syringes made of glass are prevalent in the market, but plastic counterparts are gaining popularity due to their strength, safety, and affordability.

• The strategic partnerships between local manufacturers and international pharmaceutical companies are increasing the speed of technology transfer, enhancing local production capabilities, and ensuring adherence to regulatory standards.

• Singapore and Vietnam are among the emerging countries that are becoming major investment destinations, and this is facilitated by government efforts in healthcare and the growing biologics production infrastructure.

• The competitive presence in the market is growing, and companies are investing in R&D, material innovation, and automation to enhance precision, risk reduction, and contamination, and fulfill the growing demand for ready-to-use injectable formats in the region.

According to a new report by UnivDatos the Southeast Asia Prefilled Syringes Market is expected to reach USD Million in 2033 by growing at a CAGR of 8.77% during the forecast period (2025- 2033F). The primary factors driving the Southeast Asia Prefilled Syringes Market are the rising prevalence of chronic diseases, increasing demand for biologics and biosimilars, and the growing number of vaccinations. The rapid development of healthcare facilities in the region, along with an increased adoption of minimally invasive forms of drug delivery and a shift toward home-based treatments, is also driving growth. Additionally, the growing demand to minimize cross-contamination and reduce dosing errors caused by the use of multiple-use sterile instruments is driving market expansion, facilitated by regulatory efforts to promote safer injectable delivery solutions. Moreover, the increasing demand is forcing local and multinational players to increase their investments.

On April 24, 2025, SCG Packaging Public Company Limited, also known as SCGP, announced that the company is implementing a strategy to enhance its capabilities in the growing healthcare supplies market, which continues to show strong growth potential. This involves entering the syringes and needles market. The company’s board of directors approved an investment project to expand syringes production capacity by 180 million units per year and needles production by 100 million units per year at VEM (Thailand) Company Limited (VEM-TH) in SCGP, Rayong Province, with a total investment of Baht 142.3 million (~USD 4.37 million). Production is expected to begin in January 2026.

Access sample report (including graphs, charts, and figures): https://univdatos.com/reports/southeast-asia-prefilled-syringes-market?popup=report-enquiry

Driver: Rising Demand for Biologics and Vaccines

The increased demand for biologics and vaccines is one of the driving forces of the Southeast Asia Prefilled Syringes market. As the region is experiencing a rapid pace of biologic drug development and expanding immunization initiatives, drug companies are moving towards the use of prefilled syringes to ensure precise dosing and to minimize the chances of contamination. The COVID-19 crisis has increased the speed of vaccine infrastructure, and nations such as Singapore, Vietnam, and Indonesia have invested in an efficient drug delivery format. Prefilled syringes are convenient, sterile, and time-saving, and would be the best choice when using biologic formulations that need to be handled with care. This is an increasing biologics pipeline, which is driving manufacturers to automation and ready-to-use syringe solutions across the region.

On April 3, 2025, RV Group announced a USD 20 million investment in an EU/WHO-GMP compliant sterile injectable (aseptic) facility at its existing OPO Vietnam location, representing the first advanced manufacturing hub for oncology and biosimilars in Vietnam.

Key Details:

• Facility uses ready-to-use prefilled syringes (0.5-5ml), vials, and cartridges with a robotic arm system

• Products to be manufactured:

  • Trastuzumab (cancer treatment - monoclonal antibody)

  • Bevacizumab (cancer treatment - monoclonal antibody)

  • Pegfilgrastim (oncology supportive care)

  • Semaglutide (diabetes treatment)

  • Enoxaparin (anticoagulant)

• Three-phase expansion with lyophilizer batches for 2mL, 5mL, and 10mL formulations

• First manufacturing of these advanced therapeutics in Vietnam

• Successfully passed EU-GMP audit in September 2024

Segments that transform the industry

• Based on product type, the market is segmented into staked needle syringe and luer syringe. Among these, the staked needle prefilled syringes market held the largest share in 2024. This is mainly due to its ability to provide ready-to-use, contamination-free solutions that are applicable in mass immunization and chronic care therapies. The integrated design saves on assembly time and ensures the correct dosage is administered, making it very appealing to large-scale healthcare programs. Moreover, with the growth of regional production, producers are embracing automation and safety improvements in order to fulfill the increasing demand in an efficient manner.

Region that transforms the industry

• Vietnam is expected to grow at a significant CAGR during the forecast period (2025-2033). This is mainly due to increasing healthcare investments and growing vaccination programs that drive the markets for prefilled syringes in the region. The emphasis of the government on local pharmaceutical manufacturing and production of medical devices has promoted the use of technologies and foreign collaboration. However, the rise in chronic disease and increased imports of biologics are putting a strain on high-quality injectable formats. Therefore, domestic companies are upgrading the sterile, ready-to-fill syringe production lines to meet both national and overseas demand. As foreign direct investment continues to increase and regulatory controls are enhanced, Vietnam is establishing itself as a competitive manufacturing platform. All these developments contribute to the fact that Vietnam is a strategic growth engine in the prefilled syringes industry in Southeast Asia.

Key Offerings of the Report

Market Size, Trends, & Forecast by Revenue | 2025−2033.

Market Dynamics – Leading Trends, Growth Drivers, Restraints, and Investment Opportunities

Market Segmentation – A detailed analysis of By Product Type, By Material, By Design, By Application, By Country

Competitive Landscape – Top Key Vendors and Other Prominent Vendors